Chronic%20lymphocytic%20leukemia News

News

$PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib$

PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib

Roshini Claire Anthony, 20230115100001

The second-generation BTK* inhibitor zanubrutinib was superior to the standard-of-care ibrutinib in improving progression-free survival (PFS) among patients with relapsed/refractory chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma (SLL), according to results of the phase III ALPINE trial presented at ASH 2022.

Postoperative neutropaenia tied to early CRBSI in children with leukaemia

Stephen Padilla, 20230105120000

Paediatric patients with acute myeloid leukaemia and other leukaemias (AML/OLs), especially those with persistent neutropaenia during the first 30 postoperative days, are at increased risk of early catheter-related bloodstream infections (CRBSIs), according to a Singapore study.

HIIT, resistance training boost wellbeing in chronic lymphocytic leukaemia

20220922180000

Patients with chronic lymphocytic leukaemia (CLL) may benefit from an exercise regimen consisting of high-intensity interval training (HIIT) and resistance training (RT), which could lead to better functional and general wellbeing, as well as a lower burden of lymphoma-specific symptoms, reports a recent study.

Original New Drug Application Approvals by US FDA (16 - 31 August 2022)

20220905010224

New drug applications approved by US FDA as of 16 - 31 August 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 August 2022)

20220815000000

New drug applications approved by US FDA as of 01 - 15 August 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL

Roshini Claire Anthony, 20220713180001

A time-limited regimen of venetoclax plus obinutuzumab with or without ibrutinib improved progression-free survival (PFS) in fit, treatment-naïve patients with chronic lymphocytic leukaemia (CLL), according to results of the phase III GAIA/CLL13 trial presented at EHA 2022.

Age the biggest risk factor for COVID-19 mortality in haematological cancer patients

Roshini Claire Anthony, 20220707180001

A study conducted in England has shown that in patients with haematological malignancy, the risk of COVID-19–related mortality is greatly influenced by age.

Chemoimmunotherapeutic agents boost lymphocytic leukaemia survival

20211114090000

The introduction and use of chemoimmunotherapeutic agents such as rituximab, ofatumumab, and obinutuzumab has led to population-level improvements in survival from chronic lymphocytic leukaemia (CLL), a recent study has found.

Zanubrutinib demos improved response over ibrutinib in R/R CLL/SLL

Roshini Claire Anthony, 20210720180001

Patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) may have a greater response to zanubrutinib than ibrutinib as well as better progression-free survival (PFS), according to the first interim analysis results of the ALPINE trial.

Acalabrutinib maintains efficacy over 4 years in treatment-naïve CLL

Pearl Toh, 20210630140100

Acalabrutinib with or without obinutuzumab maintains significant progression-free survival (PFS) benefit over the chemoimmunotherapy combination of obinutuzumab plus chlorambucil (O + Clb) through 4 years in treatment-naïve chronic lymphocytic leukaemia (CLL) patients, according to the phase III ELEVATE-TN study presented at EHA 2021.

Carfilzomib-based triplet regimen a potential upfront treatment for high-risk MM

Pearl Toh, 22 Oct 2020

The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.

Product Highlight - Talzenna

13 Sep 2022

Talazoparib 0.25 mg hard cap

ALL treatment: Current settings, future goals

Roshini Claire Anthony, 08 Jan 2021

Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.